Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Abstract

free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Adjuvant therapy for high‐risk cutaneous squamous cell carcinoma: 10‐year review

“…Radiation therapy (RT) uses ionizing radiation to treat sites of high‐risk cSCC tumors (Table 1). RT often uses photons in the form of external beam radiation therapy (EBRT) 43 delivered with either three‐dimensional conformal radiotherapy (3D‐CRT) or intensity‐modulated RT (IMRT) techniques, the latter of which can reduce doses to critical organs beyond the target in complex high‐risk cases 44–46 . Orthovoltage or electron beam RT techniques are commonly utilized for superficial targets 47,48 .…”

“…Doses of 50–70 Gy over 5–7 weeks, depending on extent of disease, have been recommended by the NCCN for ART in cSCC 7 . In an effort to reduce variations in treatment by clinicians and promote harmonization of PORT, and perhaps entice collaboration between committees to promote standardization, Porceddu et al recently reported consensus guidelines from the Head and Neck Cancer International Group (HNCIG) for defining specific PORT volumes and minimum doses for complex cSCC of the head and neck following primary tumor resection 44 …”

“…RT often uses photons in the form of external beam radiation therapy (EBRT) 43 delivered with either three‐dimensional conformal radiotherapy (3D‐CRT) or intensity‐modulated RT (IMRT) techniques, the latter of which can reduce doses to critical organs beyond the target in complex high‐risk cases. 44 , 45 , 46 Orthovoltage or electron beam RT techniques are commonly utilized for superficial targets. 47 , 48 Protons can also be utilized in the form of proton beam RT (PBRT), which delivers even lower doses to tissue beyond the target and, thus, may have less toxic effects.…”

A review of telephone consultations for head and neck cancer follow up: a patient satisfaction survey

“…It used a modified Delphi process to gather responses from 20 national trial groups across 3 continents. 2 Regarding oncological follow-up, the following recommendations were made. Eighty per cent of respondents strongly agreed that patients with three or more months following intervention should be monitored using telephone consultations unless there are new suspicious symptoms.…”

Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress

“…Up to now, the treatment choice for HNSCC patients is largely determined by the tumor stage at diagnosis. Commonly, HNSCC at an early stage (I or II) is treated with local therapy, such as surgical removal and/or radiation therapy, while advanced disease (stage III or IV) requires multimodality treatment with surgery, radio, and/or chemotherapy [4]. Cisplatin is one of the chemotherapeutic drugs most commonly used today for advanced HNSCC; a combination with Cetuximab (monoclonal antibody targeting EGFR) has been approved as first-line treatment for recurrent/metastatic HNSCC [5], representing, to date, the only targeted therapy approved for the treatment of HNSCC [5,6].…”